Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Commercial with water · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Eletriptan commercial tablet with water | ACTIVE_COMPARATOR | Eletriptan commercial tablet given with water |
| Eletriptan oral disintegrating tablet (ODT) #1 without water | EXPERIMENTAL | Oral disintegrating tablet formulation #1 without water |
| Oral disintegrating tablet formulation (ODT) #2 without water | EXPERIMENTAL | Oral disintegrating tablet formulation #2 without water |
| Oral disintegrating tablet formulation (ODT) #1 with water | EXPERIMENTAL | Oral disintegrating tablet formulation (ODT) #1 with water |
| Oral disintegrating tablet formulation (ODT) #2 with water | EXPERIMENTAL | Oral disintegrating tablet formulation (ODT) #2 with water |
| Name | Type | Description |
|---|---|---|
| Commercial tablet with water | DRUG | 40 mg tablet, given once to each subject |
| ODT #1 without water | DRUG | 40 mg tablet given once to each subject |
| ODT #2 without water | DRUG | 40 mg tablet given once to each subject |
| ODT #1 with water | DRUG | 40 mg tablet given once to each subject |
| ODT #2 with water | DRUG | 40 mg tablet given once to each subject |
Inclusion Criteria: * Healthy subjects * No CYP3A4 inhibitors Exclusion Criteria: * Clinically significant disease in any organ system * Positive urine drug screen
Commercial with water is a small molecule drug being developed by Pfizer, Inc. for use in healthy volunteers. It is currently in Phase 1 clinical development. The drug is being studied in a pharmacokinetic trial to evaluate its absorption and processing in the body.
Commercial with water is being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with the goal of understanding how the drug behaves in the body. The specific therapeutic indication has not been established, as it is still in early-stage research.
Commercial with water is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
Commercial with water is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated in healthy volunteers.
Commercial with water has one completed clinical trial, NCT00871806, which studied the pharmacokinetics of two eletriptan oral formulations given with and without water and the commercial tablet formulation given with water. The trial enrolled 20 healthy volunteers in Singapore.
Commercial with water is not the same as eletriptan. It is a formulation of eletriptan, a small molecule drug, being studied in a pharmacokinetic trial. The trial compares different oral formulations of eletriptan, including the commercial tablet, to understand their absorption when taken with or without water.